AstraZeneca PLC ASTRAZENECA PRICES A $2BN BOND ISSUE (2066H)
06 June 2017 - 4:01PM
UK Regulatory
TIDMAZN
RNS Number : 2066H
AstraZeneca PLC
06 June 2017
6 June 2017 07:00 BST
ASTRAZENECA PRICES A $2BN BOND ISSUE
AstraZeneca PLC announces that, on 5 June 2017, it priced a
three tranche Global bond offering totalling $2bn. The offering is
expected to close on 12 June 2017, subject to customary closing
conditions. AstraZeneca expects to use the net proceeds of the
issue for general corporate purposes which may include the
refinancing of existing indebtedness. The transaction, which is a
global offering registered with the US Securities and Exchange
Commission (SEC), consists of the following three tranches:
-- $1bn of 5 year fixed rate notes with a coupon of 2.375%;
-- $0.75bn of 10 year fixed rate notes with a coupon of 3.125%; and
-- $0.25bn of 5 year floating rate notes.
Barclays, BofA Merrill Lynch, HSBC and Morgan Stanley acted as
joint-bookrunning managers on the transaction. The notes will be
issued under AstraZeneca's effective shelf registration statement
on Form F-3, which AstraZeneca filed with the SEC on 22 November
2016. The offering is being made solely by means of the prospectus
contained within that shelf registration statement, along with a
prospectus supplement forming part of the effective registration
statement, which investors should read.
A copy of the prospectus supplement and accompanying prospectus
relating to the offering can be obtained by contacting Barclays
Capital Inc. c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, by telephone at 1-888-603-5847 or by
email at barclaysprospectus@broadridge.com; HSBC Securities (USA)
Inc., 452 Fifth Avenue, New York, NY 10018, Attention: Transaction
Management Group, by telephone at 1-866-811-8049; Merrill Lynch,
Pierce, Fenner & Smith Incorporated, NC1-004-03-43, 200 North
College Street, 3rd floor, Charlotte NC 28255-0001, Attention:
Prospectus Department, by telephone at 1-800-294-1322 or by email
at dg.prospectus_requests@baml.com; or Morgan Stanley & Co.
LLC, Attention: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, NY 10014, by telephone at 1-866-718-1649 or by
email at prospectus@morganstanley.com. You may also download these
documents for free by visiting EDGAR on the SEC website at
www.sec.gov.
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such jurisdiction.
The bond issuance does not impact the Company's financial
guidance for 2017.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of autoimmunity, neuroscience and infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide.
Cautionary Statements Regarding Forward-Looking Statements
This announcement contains certain forward-looking statements
with respect to the operations, performance and financial condition
of AstraZeneca. Although we believe our expectations are based on
reasonable assumptions, any forward-looking statements, by their
very nature, involve risks and uncertainties and may be influenced
by factors that could cause actual outcomes and results to be
materially different from those predicted. The forward-looking
statements reflect knowledge and information available at the date
of preparation of this announcement and AstraZeneca undertakes no
obligation to update these forward-looking statements.
Media Relations
Esra Erkal-Paler UK/Global +44 203 749 5638
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Nick Stone Respiratory +44 203 749 5716
Christer Gruvris Autoimmunity, Neuroscience & Infection +44 203 749 5711
US toll free +1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
This information is provided by RNS
The company news service from the London Stock Exchange
END
IODUVOARBRANRUR
(END) Dow Jones Newswires
June 06, 2017 02:01 ET (06:01 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024